CDX General Discussion 2025, page-73

My key take aways;

1/ A Pharma Group order is $675k AUD at $280 USD per device, 1,500 devices.

2/ "with an average sales price of approximately US$320 (including any discounts) and a daily sales volume of around 30 units, we’re looking at an annual run rate of approximately US$3.5 million by the end of Q3."

Based upon this they're anticipating just under 11,000 devices to be sold by the end of Q3, and I agree from a starting point this would be incredible growth.

3/ "We anticipate receiving TGA approval in Australia and Medsafe in NZ by mid 2025 - and CE approval in Europe in the second half of calendar 2025" This will be huge.

4/ "We are continuing with preparations for FDA clearance submission on OTC for the Pulse. Our initial usage data on the Pulse forms an important part of that submission which we are collating as part of the overall submission."

5/ A focus on cost saving / profit " An overall saving of 34% (US$1M) is expected over CY25"

Then there's the 4C, receipts and cashburn aren't overly encouraging, but CDX has just kicked off the Pulse. Quite bullish all aspects considered, I think the Pulse will be a company maker over the next 12 months.